Search research articles
Contact Us
Filters
Showing results (141-150 of 153) with videos related to
Page
of 16
Sort By:
Signal Transduction and Targeted Therapy
|
April 16, 2024
Phase II study of novel orally PI3Kα/δ inhibitor TQ-B3525 in relapsed and/or refractory follicular lymphoma
Huaqing Wang, Jifeng Feng, Yanyan Liu, et al.
Blood Cancer Journal
|
March 18, 2026
Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26)
Juying Wei, Qingqing Cai, Liling Zhang, et al.
Journal of Translational Internal Medicine
|
December 22, 2023
Efficacy and safety of QL0911 in adult patients with chronic primary immune thrombocytopenia: A multicenter, randomized, double-blind, placebo-controlled, phase III trial
Hu Zhou, Shouqing Han, Jie Jin, et al.
Molecular Biology Reports
|
June 17, 2011
miR-29a and miR-142-3p downregulation and diagnostic implication in human acute myeloid leukemia
Fang Wang, Xiao-Shuang Wang, Gui-Hua Yang, et al.
Science Bulletin
|
March 24, 2026
Comprehensive understanding of new particle formation in China through advanced modeling
Jiewen Shen, Bin Zhao, An Ning, et al.
Age and Ageing
|
October 21, 2021
Comprehensive geriatric assessment in newly diagnosed older myeloma patients: a multicentre, prospective, non-interventional study
Yuan Yao, Wei-Wei Sui, Ai-Jun Liao, et al.
Annals of Hematology
|
December 19, 2023
Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial
Huixing Zhou, Yafei Wang, Jiao Chen, et al.
Journal of Cancer Research and Clinical Oncology
|
April 11, 2024
Oral arsenic plus imatinib versus imatinib solely for newly diagnosed chronic myeloid leukemia: a randomized phase 3 trial with 5-year outcomes
Jie Tian, Yong-Ping Song, Gao-Chong Zhang, et al.
Blood Advances
|
September 18, 2024
Asymptomatic multicentric Castleman disease: a potential early stage of idiopathic MCD
Lu Zhang, Qin-Hua Liu, Hui Zhou, et al.
The Lancet Regional Health. Western Pacific
|
June 7, 2023
A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria
Lu Zhang, Yu-Jun Dong, Hong-Ling Peng, et al.
Page
of 16
Search research articles
Search
Showing results (141-150 of 153) with videos related to
Sort By:
Page
of 16
Signal Transduction and Targeted Therapy
|
April 16, 2024
Phase II study of novel orally PI3Kα/δ inhibitor TQ-B3525 in relapsed and/or refractory follicular lymphoma
Huaqing Wang, Jifeng Feng, Yanyan Liu, et al.
Blood Cancer Journal
|
March 18, 2026
Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26)
Juying Wei, Qingqing Cai, Liling Zhang, et al.
Journal of Translational Internal Medicine
|
December 22, 2023
Efficacy and safety of QL0911 in adult patients with chronic primary immune thrombocytopenia: A multicenter, randomized, double-blind, placebo-controlled, phase III trial
Hu Zhou, Shouqing Han, Jie Jin, et al.
Molecular Biology Reports
|
June 17, 2011
miR-29a and miR-142-3p downregulation and diagnostic implication in human acute myeloid leukemia
Fang Wang, Xiao-Shuang Wang, Gui-Hua Yang, et al.
Science Bulletin
|
March 24, 2026
Comprehensive understanding of new particle formation in China through advanced modeling
Jiewen Shen, Bin Zhao, An Ning, et al.
Age and Ageing
|
October 21, 2021
Comprehensive geriatric assessment in newly diagnosed older myeloma patients: a multicentre, prospective, non-interventional study
Yuan Yao, Wei-Wei Sui, Ai-Jun Liao, et al.
Annals of Hematology
|
December 19, 2023
Efficacy and safety of generic pomalidomide plus low-dose dexamethasone in relapsed or refractory multiple myeloma: a multicenter, open-label, single-arm trial
Huixing Zhou, Yafei Wang, Jiao Chen, et al.
Journal of Cancer Research and Clinical Oncology
|
April 11, 2024
Oral arsenic plus imatinib versus imatinib solely for newly diagnosed chronic myeloid leukemia: a randomized phase 3 trial with 5-year outcomes
Jie Tian, Yong-Ping Song, Gao-Chong Zhang, et al.
Blood Advances
|
September 18, 2024
Asymptomatic multicentric Castleman disease: a potential early stage of idiopathic MCD
Lu Zhang, Qin-Hua Liu, Hui Zhou, et al.
The Lancet Regional Health. Western Pacific
|
June 7, 2023
A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria
Lu Zhang, Yu-Jun Dong, Hong-Ling Peng, et al.
Page
of 16